Greater China holds a significant, if not the world’s largest, acute heart failure patient population. It may be a market where drug treatment innovation can help patients and that’s what Windtree Therapeutics Inc. (NASDAQ: WINT) is hoping to accomplish with its new license agreement with Lee’s Pharmaceutical (HK) Ltd.
Windtree Therapeutics and Lee’s Pharmaceutical are teaming up to develop and commercialize Windtree’s product candidate istaroxime for acute heart failure and cardiogenic shock for the greater China region. In addition to istaroxime, the agreement also licenses Windtree’s preclinical next-generation dual mechanism SERCA2a activators and rostafuroxin, a phase 2 product candidate for hypertension associated with specific genotypes.
Windtree’s Pipeline Supported With Deal As Company Also Potentially Gains Non-Dilutive Development Resources
The deal supports Windtree’s pipeline treatments for acute heart failure and cardiogenic shock and has the potential to provide financial support for development of treatment to address an unmet need and a growing problem in China.
“We believe Windtree’s pipeline has great potential and we expect this license agreement will progress development in the treatment of heart failure. We see the agreement as validation of the significant heart failure market opportunity for istaroxime and, when coupled with the unique profile and our ...